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A B S T R A C T
Photochemical Internalisation (PCI) is a novel drug delivery technology in which low dose photodynamic
therapy (PDT) can selectively rupture endo/lysosomes by light activation of membrane-incorporated
photosensitisers, facilitating intracellular drug release in the treatment of cancer. For PCI to be developed
further, it is important to understand whether nerve damage is an impending side effect when treating
cancers within or adjacent to nervous system tissue. Dorsal root ganglion (DRG) neurons and their
associated satellite glia were subjected to PCI treatment in a 3D co-culture system following incubation
with photosensitisers: meso-tetraphenylporphine (TPPS2a) or tetraphenylchlorin disulfonate (TPCS2a)
and Bleomycin. Results from the use of 3D co-culture models demonstrate that a cancer cell line PCI30
and satellite glia were more sensitive to PCI than neurons and mixed glial cells, athough neurite length
was affected. Neurons in culture survived PCI treatment under conditions sufﬁcient to kill tumour cells,
suggesting cancers within or adjacent to nervous system tissue could be treated with this novel
technology.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Photochemical Internalisation (PCI) is a novel photochemical
technology that facilitates the delivery of molecules into the
cytosol of the cell. In PCI, a photosensitiser together with a
therapeutic agent taken up via endocytosis. Exposure to light leads
to endosomal rupture and the release of the therapeutic agent into
the cytosol. The membrane rupture occurs through oxidative
damage from ROS generated by the photosensitiser, but the light
and photosensitiser doses used in PCI are too small to exert a lethal
effect (in contrast to Photodynamic therapy (PDT), where the
reactive oxygen species (ROS) damage induced by the photo-
sensitiser is directly cytotoxic). There are a number of advantagesAbbreviations: PCI, Photochemical Internalisation; PDT, Photodynamic therapy;
ROS, Reactive oxygen species; HNC, Head and neck cancer; TPPS2a, Meso-
tetraphenylporphine; TPCS2a, Tetraphenylchlorin disulfonate; 3D, Three-dimen-
sional; DRG, Dorsal root ganglion; CNS, Central nervous system.
* Corresponding author.
E-mail address: j.woodhams@ucl.ac.uk (J.H. Woodhams).
http://dx.doi.org/10.1016/j.ijpharm.2017.05.071
0378-5173/© 2017 The Authors. Published by Elsevier B.V. This is an open access articlfor using PCI for drug delivery: it is site-speciﬁc and the enhanced
delivery efﬁciency enables lower drugs doses to be applied using
systemic administration (Selbo et al., 2002). By harnessing the
improved delivery efﬁciency conferred by PCI, many of the
unwanted side effects associated with using drugs with a
molecular weight in excess of 1000 Da are reduced. For example
it has been estimated that, once in the cytosol, as few as 500
Bleomycin molecules are sufﬁcient to kill a cell (Poddevin et al.,
1991).
PCI has potential to be an important new therapy for treatment
of many cancers including head and neck cancer (HNC), bladder,
and prostate. But for this treatment to be developed further, it is
important to understand whether nerve damage is a potential side
effect of PCI. To date many studies of PDT have described and
conﬁrmed nerve sparing even when the nerves are within the
treatment ﬁeld (Betz et al., 2007,DE Visscher et al., 2013, Green
et al., 2013, Lou et al., 2004, Dole et al., 2005, Kubler et al., 2003). In
experimental investigations to understand the clinical nerve
sparing reported during certain PDT treatments, Wright et al.,
used 3D co-culture models to recreate the neuron-gliale under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
134 C. O’Rourke et al. / International Journal of Pharmaceutics 528 (2017) 133–143interactions and physical environment that inﬂuence neural cells
and this approach enabled nerve-sparing photosensitisers to be
distinguished from those that damage nerves (Wright et al., 2009).
Importantly, a clinically-relevant mTHPC-mediated PDT treatment
regime was identiﬁed which killed human breast cancer cells
(MCF-7) in culture but spared neurons, reﬂecting the clinical
observations associated with mTHPC (Wright et al., 2009).
Subsequent studies using the same co-culture approach revealed
the biochemical pathways likely to be responsible for the nerve
sparing effect (Wright et al., 2012).
An efﬁcient photosensitiser for PCI is meso-tetraphenylpor-
phine (TPPS2a), which has two sulfonate groups on adjacent
phthalate/phenyl rings. This amphiphilic structure with both a
hydrophobic part and a hydrophilic part enables the photo-
sensitiser to bind to the cell membrane and be taken up via
adsorptive endocytosis (Friberg et al., 2003). A disadvantage of
porphyrin photosensitisers is that they exhibit weak absorption at
red/NIR wavelengths, which are used therapeutically since light in
this wavelength range can penetrate more deeply into tissue. This
led to the development of a chlorin based photosensitiser for PCI
with two adjacent sulfonated groups which exhibits improved red
wavelength absorption c. 650 nm, (TPCS2a, tetraphenylchlorin
disulfonate). TPCS2a has a low toxicity and high speciﬁcity towards
endo/lysosomal membranes in tumour cells owing to its amphi-
philic structure (Gaware et al., 2013). The clinically used
formulation of this photosensitiser is known as AmphinexTM.
Bleomycins are a family of water-soluble glycopeptidic anti-
biotics with at least four functional domains mediating DNA
breakage, ion binding and O2 activation (Katare et al., 2014, Berg
et al., 2011). Enhanced efﬁcacy of PCI with Bleomycin has been
documented in several preclinical studies and no severe side
effects have been reported to date (Norum et al., 2009, Berg et al.,
2010). Although Cisplatin, Carboplatin, Docetaxel and Gemcitabine
are more commonly used in HNC therapy, their suitability for PCI is
not fully established and some of these agents by themselves are
reported to cause neurotoxicity (Mcwhinney et al., 2009, Park et al.,
2013). A phase 1 clinical trial focused on treatment of head and
neck cancer illustrated that TPCS2a-mediated photochemical
internalisation of Bleomycin is safe and tolerable and further
identiﬁed treatment doses (Sultan et al., 2016).
The effect of low dose TPCS2a/TPPS2a PDT as well as the direct
release of Bleomycin by PCI to nervous system tissue is unknown.
Neurons have highlyadaptedsystems for the axoplasmic transportof
vesicles over greater distances than other cells, endo/exocytosis is
coupled to electrochemical activity at synapses, and there is growing
evidence for exosome movement between neurons and glia (Fang
et al., 2015). These features, combined with the ability of neurons to
resist ROS-mediated damage (Wright et al., 2012), make the effect of
PCI on nerve cells hard to predict. The aim of this study was to
investigate the effects of PCI agents on nervous system cells in 3D co-
cultures. In line with the phase 1 clinical trial that used PCI to treat
head and neck cancer, a cancer cell line representative of a head and
neck squamous cell carcinoma (PCI30) was chosen for study
alongside neural cells. Cells were organised within collagen hydro-
gels and treated with combinations of photosensitisers, chemother-
apeutic agents and light. The sensitivity of neurons and glia to PCI
treatments was investigated and compared to the PCI30 cell line in
order to identify approaches that minimise nerve toxicity.
2. Materials and methods
2.1. Cell cultures
2.1.1. Mixed glial cells
All experiments were performed according to the UK Animals
(Scientiﬁc Procedures) Act (1986) and approved by the appropriateinstitutional ethical committee. Cortical mixed glial cells were
isolated from cerebral cortices of postnatal, 2 day old (P2), Sprague
Dawley rats, as adapted (Mccarthy and Devellis,1980) and by (Chen
et al., 2007). The cortices were ﬁnely chopped, placed in digest
solution (0.2 mg/ml DNase, 250 mg/ ml trypsin in HBSS with Ca2+
and Mg2+ and 1% penicillin/streptomycin (P/S)) for 15 minutes at
37 C. Subsequently, 10 ml DMEM containing 20% fetal calf serum
(FCS) and 1% P/S (DMEM20S) was added and the cell suspension
centrifuged for 5 minutes at 100 x g. The tissue pellet was
resuspended in 20 ml DMEM20S and triturated with a 10 ml
pipette followed by a Pasteur pipette, then a ﬁre-polished Pasteur
pipette. Following trituration, the suspension was left to settle on
ice then the cell supernatant was passed through a 70 mm cell
strainer and the top fraction containing dissociated cells collected.
This process was repeated once more and cells were seeded into
T75 ﬂasks coated with 20 mg/ml poly-D-lysine (PDL) at a ratio of 1
brain per ﬂask in DMEM20S. Flasks were placed in a humidiﬁed
incubator at 37 C with 5% CO2, 95% air, with a media change
weekly and cells were cultured for 2 weeks before use.
2.1.2. DRG Neurons/Satellite glia
Neurons and satellite glial cells were cultured from dorsal root
ganglia (DRGs), twenty of which were isolated from each freshly
culled 250–350 g Sprague Dawley rat as previously described
(Phillips et al., 2005). Using microscopic dissection, DRGs were
removed, cleaned of all nerve roots and incubated for 90 min at
37 C in Dulbecco's Modiﬁed Eagle's Medium (DMEM) containing
0.125% collagenase (Sigma), then triturated to produce a cell
suspension. Culture medium (DMEM supplemented with 10% FCS
and 1% P/S) was added and cells were separated from the
collagenase by centrifugation for 5 min at 100 x g and resuspended
in an appropriate volume of culture medium.
2.1.3. Cell Lines
The tumour cells used in this study were the head and neck
squamous cell carcinoma cell line, PCI30 (Lechner et al., 2013)
(Generous gift from Dr Tim Fenton). PCI30 cells were cultured in
T75 ﬂasks in fully supplemented DMEM until 95% conﬂuent
whereupon they were removed using trypsinisation (0.25%
trypsin–EDTA, 5 min, 37 C). Cells were washed by centrifugation
for 5 min at 100 x g and resuspended in an appropriate volume of
culture medium.
2.1.3.1. Cell culture models. Monolayer and three-dimensional (3D)
cell culture models were used in this study. Analysis of
photosensitiser uptake, co-localisation and assessment of
neurite length were conducted using cells in monolayer
cultures, whereas cell death assays used 3D cultures in order to
trap non-adherent cells that would have been lost from monolayer
cultures following treatment (Wright et al., 2009).
For monolayer cell culture, neural cells and PCI30 cells were
grown on glass coverslips coated with 20 mg/ml PDL. Cells were
seeded in 100 ml of culture medium (3.5 104 cells/ml), allowed to
adhere for 30 min, then incubated in 1 ml culture medium in 12-
well culture plates.
For 3D cultures, gels were prepared using 80% v/v Type I rat tail
collagen (2 mg/ml in 0.6% acetic acid; First Link) mixed with 10% v/
v 10  minimum essential medium (Sigma) and the mixture
neutralised using 5.8% v/v neutralising solution (TAP Biosystems)
before addition to 4.2% v/v cell suspension. 200 ml of the mixture,
each containing 5 104 of either DRG neurons/Satellite glia, mixed
glial cells or PCI30 cells was added to individual wells of a 24-well
plate and the gels were allowed to set at 37 C for 10 min. Cellular
gels were then immersed in 500 ml culture medium and
maintained in culture at 37 C, 5% CO2, for 4 days (DRG cells/
Satellite glia) or 1 day (PCI30 and mixed glial cells) before
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time for proliferation of these rapidly dividing cells, whilst 4 days
allowed neurite extension of DRG neurons.
2.2. Photochemical Internalisation
Culture medium was removed from coverslips or gels and
cultures were incubated with photosensitiser drugs; TPCS2a or
TPPS2a (based on previous in vitro studies with similar photo-
sensitisers (Wang et al., 2013, Berg et al., 2010)) and/or the
chemotherapeutic drug Bleomycin diluted in culture medium for
18 hrs in the dark at 37 C, 5% CO2. The medium containing the drug
compounds was removed, and the cultures washed with phos-
phate-buffered saline (PBS) before addition of fresh culture
medium, and cultures were then incubated for a further 4 hrs.
Cultures were then exposed to LED light with a peak wavelength of
420 nm and a ﬂuence rate of 1.5 mW/cm2 (Thorlabs; 1000 mA,
750 mW) for 5 min, giving a total light dose of 0.6 J/cm2.The
minimal thickness (<1 mm), relatively low cell density and
transparent nature of the collagen gels ensured that all cells
within them received an equivalent light dose (Wright et al., 2009).
Controls were included in each experiment that involved excluding
either the drug or the light (by wrapping the plate in foil during the
illumination step) or both. Following incubation, gels and cover-
slips were incubated at 37 C, 5% CO2 for a further 24 hrs unless
otherwise stated.
2.2.1. Fluorescence spectroscopy
PCI30 and neural cells were seeded into 96-well plates at 2–
2.5 104 cells per well overnight and then incubated with either
TPCS2a or TPPS2a at different concentrations for 18 hrs. Thrice
washing of cells and a further 4 hrs incubation with fresh culture
medium was then carried out. The medium was replaced with clear
medium (DMEM without phenol red or serum) for ﬂuorescence
measurements with excitation at 420 nm and detection at 650 nm
using a LS50 B ﬂuorescence spectrometer (Perkin Elmer) equipped
with a 96-well plate reader and mean intracellular ﬂuorescence for
each photosensitiser calculated. Fluorescence from control cells
without exposure to the photosensitiser was negligible.
2.3. Immunocytochemistry
Following ﬁxation, cell permeabilisation was performed using
0.5% TritonX-100 (Sigma) for 30 min. Following 3  5 min washes,Fig.1. Uptake of TPCS2a and TPPS2a by neural and PCI30 cells. Fluorescence intensity at 66
and DRG neurons/Satellite glia following 18 hrs incubation with an excitation wavelengnon-speciﬁc binding was blocked with 5% normal goat serum
(Dako) in PBS for 30 min. After another wash step, primary
antibodies were diluted 1:400 in PBS (mouse anti-b III-tubulin;
Sigma) and incubated overnight at 4 C. Following 3  10 min
washes, secondary antibody, anti-mouse IgG DyLight 488 (Vector
Laboratories) was diluted 1:300 in PBS and added for 90 min.
Hoechst 33258 (1 mg/ml) was also added into the secondary
antibody incubation to stain nuclei. Omission of a primary or
secondary antibody was routinely used as a control. Incubation
times for coverslips were half that for gels except for an overnight
incubation in primary antibodies. Gels and coverslips were stored
in PBS at 4 C.
2.4. Cell death assay
Cell death was assessed using propidium iodide (PI; Sigma)
staining in combination with Hoechst 33258. Brieﬂy, PI was added
to cultures at 200 mg/ml in cell culture medium and left to incubate
for 15 min at 37 C. The medium was then removed and the
cultures were rinsed in PBS before ﬁxing in 4% paraformaldehyde
(PFA) at 4 C. Gels were incubated with Hoechst 33258 (1 mg/ml;
Sigma) in PBS for 10 min, before 3  5 min washes in PBS.
Fluorescence microscopy was used to determine cell viability.
Images were captured using a Zeiss Axiolab A1 ﬂuoroscence
microscope and Zeiss AxioCam C1. Three ﬁelds were randomly
selected per gel. The % of dead cells for each cell population was
determined by counting the number of PI stained cells and the total
number of cells, as determined by Hoechst staining. For neurons,
the number of bIII-tubulin immunopositive cells was calculated as
a percentage of the total number of cells/ﬁeld and compared to the
number of PI stained cells to determine cell death.
2.5. Image analysis and quantiﬁcation
Neurite length was determined from images captured using the
ﬂuorescence microscope. The length of each neurite captured per
image was measured by manual tracing using ImageJ.
Confocal microscopy (Zeiss LSM 710) was used to capture
images for analysis of co-localisation. LysoTracker1 Green DND-26
(ThermoFisher Scientiﬁc) was used to label lysosomes and their
localisation relative to the photosensitiser was determined.
Colocalization analysis was performed on single-plane confocal
images (3 images per coverslip) using VolocityTM 6.4 (Perkin
Elmer) software which calculated the Pearson’s correlation0 nm of 0.05–0.8 mg/ml (A) TPCS2a and (B) TPPS2a taken up by PCI30, mixed glial cells
th of 420 nm. Mean  SEM, n = 3.
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measures the strength of the association between the two
ﬂuorescents giving values of between +1 and 1, where +1
suggests a total positive correlation, 0 is no correlation and 1 a
total negative correlation. Similarly, the overlap coefﬁcient
measures co-localisation of ﬂuorescent signals to generate values
between 0-1, with 0 being no overlap and 1 perfect image
registration.
2.6. Statistical analysis
Normality tests were performed on all data to determine which
test was appropriate and one-way ANOVA or t-tests were
performed if data followed a normal distribution. A one-way
ANOVA was followed by a Dunnett’s post hoc test to compare
multiple conditions against the control, or Tukey’s multiple
comparisons test to compare groups. When comparing the mean
differences between groups that have been split on two indepen-
dent variables a two-way Anova was performed. For all tests,
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 were consid-
ered to be signiﬁcant.
3. Results
3.1. Increasing uptake of photosensitisers TPCS2a and TPPS2a with
increasing concentrations by neural cells
PCI30 and neural cells were incubated with TPCS2a and TPPS2a
using a range of concentrations from 0.05  0.8 mg/ml for 18 hrs
following which the mean intracellular ﬂuorescence for each
photosensitiser was assessed. For each cell type, the ﬂuorescenceFig. 2. Photosensitisers localise to lysosomes within cells. Confocal micrographs exhibit
within neural cells. Scale bar = 35 mm. (B) and (D) Pearson’s correlation coefﬁcient, (C) an
as a marker for endosomes. Mean  SEM, n = 3.intensity for TPCS2a at concentrations of 0.2–0.8 mg/ml was much
greater when compared to that of TPPS2a (Fig. 1A and B).
Additionally, PCI30 cells exhibited considerably greater ﬂuores-
cence intensity than neural cells when incubated with higher
concentrations of TPCS2a, suggesting greater uptake of the
photosensitiser (see Fig. 1A).
3.2. Photosensitisers TPCS2a and TPPS2a localise within endosomes in
neural cells
Confocal micrographs conﬁrm that both TPCS2a and TPPS2a
localised within endosomes intracellularly, as seen in Fig. 2.
Photosensitiser colocalisation with lysotracker was analysed via
quantitative analysis of confocal images. Two different values were
calculated; the Pearson’s correlation coefﬁcient and the overlap
coefﬁcient (Dunn et al., 2011). For TPCS2a, both Pearson’s
correlation coefﬁcient and overlap coefﬁcient values were higher
in PCI30 cells at all concentrations compared to mixed glial cells
and DRG/satellite glia, suggesting a greater proportion of photo-
sensitiser could be located within the endosomes of the cancer cell
line. This same was not true for TPPS2a with no deﬁnitive pattern
observed for both Pearson’s correlation coefﬁcient and overlap
coefﬁcient values.
3.3. Neural cells display limited dark toxicity in the presence of TPCS2a
and TPPS2a
To establish whether the presence of photosensitisers in culture
have a toxic effect upon neurons and mixed glial cells in the
absence of light, PCI30 and neural cells were incubated with TPCS2a
and TPPS2a using a range of concentrations from 0.05–0.8 mg/ml co-localisation of lysotracker (green) and photosensitisers (red), TPCS2a and TPPS2a
d (E)overlap coefﬁcient illustrating the overlap photosensitiser and lysotracker used
Fig. 2. (Continued)
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photosensitisers which is minimal for all cells types with neither
neural cells nor the cancer cell line showing signiﬁcant cell death in
the presence of the compounds, as seen in Fig. 3.
3.4. Phototoxicity of TPCS2a and TPPS2a
The phototoxicity induced by both TPCS2a and TPPS2a was
investigated at a range of concentrations under a light exposure of
0.6 J/cm2. Dose dependent cell death was found with both
photosensitisers and it was noted that higher concentrations of
TPPS2a (0.4–0.8 mg/ml) resulted in higher cell death when
compared to equivalent concentration of TPCS2a (Fig. 4). FromFig. 3. Dark toxicity of TPCS2a and TPPS2a. PCI30, primary mixed glial cells, neurons and 
which showed to have minimal effect upon cell viability. Mean  SEM, n = 6.this information, a starting concentration of 0.2 mg/ml was chosen
for subsequent PCI experiments due to these concentrations
achieving approximately 50% cell death (PDT50) of PCI30 cells.
Determination of treatment conditions corresponding to the PDT50
is important when selecting the optimum treatment parameters
for PCI where a sub-lethal PDT effect is the aim.
3.5. Increasing concentrations of Bleomycin results in increased cell
death
The cytotoxicity induced by the anti-cancer drug Bleomycin
with and without light was examined prior to the combination
with PDT treatment. In control gels without any applied drug butsatellite glia were incubated with 0.5–0.8 mg/ml (A) TPCS2a or (B) TPPS2a for 18 hrs,
Fig. 4. Phototoxicty of TPCS2a and TPPS2a. PCI30, primary mixed glial cells, neurons and satellite glia were incubated with 0.05–0.8 mg/ml TPCS2a or TPPS2a for 18 hrs. Cells
were irradiated 0.6 J/cm2 using an LED light source with a wavelength of 420 nm. Results are shown as mean percentage cell death against increasing concentrations of
photosensitiser. Mean  SEM, n = 6.
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Bleomycin produced similar toxicity in neurons, satellite glia,
mixed glial cells and neurons alone and the presence of the light
did not increase death signiﬁcantly, as revealed by t-tests. PCI30
cell death did however appear to increase in the presence of light,
albeit not signiﬁcantly as examined by a t-test (Fig. 5).
3.6. Cytotoxicity of TPCS2a PCI combining Bleomycin
The effect of using PCI to release Bleomycin was investigated
using TPCS2a with approximately the PDT50 doses (0.2, 0.4 andFig. 5. Cytotoxicity of Bleomycin with or without light exposure. DRG neurons, satell
Bleomycin for 18 hrs. Cells were illuminated with 0.6 J/cm2 using a LED light source wit
death due to illumination. Mean  SEM, n = 6.0.8 mg/ml (Fig. 4A)). All gels were incubated with drugs for 18 hrs
and light exposures of 5 mins were employed for each case to give a
total light dose of 0.6 J/cm2. For all concentrations, neuronal cell
death was signiﬁcantly lower than that of the PCI30 cell line,
suggesting neurons are more resistant to this treatment than PCI30
cells. Mixed glial cells also exhibited less cell death than the cancer
cell line. Satellite glia displayed a high percent of cell death
following treatment, particularly in the presence of higher
concentrations of Bleomycin, indicating that the satellite glia
were more susceptible to PCI treatment than neurons and mixed
glial cells (Fig. 6).ite glia, PCI30, and mixed glial cells were incubated with 0.00175–0.014 IU/ml of
h a wavelength of 420 nm and t-test results revealed no signiﬁcant increases in cell
Fig. 6. Sensitivity of cells to TPCS2a PCI of Bleomycin. PCI30, mixed glial cells, neurons and satellite glia incubated with 0.2–0.8 mg/ml TPCS2a and 0.00175–0.07 IU/ml of
Bleomycin for 18 hrs before irradiation using a LED light source. Two-way ANOVA revealed a main effect of cell type, as well as concentration of TPCS2a in increased cell death
and an interaction between cell type and TPCS2a concentration. Mean  SEM, n = 6.
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The PCI effect combining Bleomycin in primary neural cells and
PCI30 cells was investigated using TPPS2a with approximately the
PDT50 doses. All gels were incubated with drugs for 18 hrs and light
exposures of 5 mins were employed for each case. Similar to results
obtained for TPCS2a neuronal cell death was signiﬁcantly lower
than that of the PCI30 cell line for all concentrations of both TPPS2a
and Bleomycin. Satellite glia however exhibited similar levels of
cell death as PCI30 cells, much higher than neurons or mixed glial.
Mixed glial cells appear to exhibit greater cell death than neurons
in the presence of TPPS2a.
3.8. No increased neuronal death 48 and 72 hours post treatment with
TPCS2a PCI of Bleomycin
The PCI effect over time in combination with 0.07 IU/ml
Bleomycin in primary neural cells and the PCI30 cancer cell linewas investigated using 0.8 mg/ml TPCS2a. Similar to previous
experiments, all gels were incubated with drugs for 18 hrs and light
exposures of 5 mins were employed for each case. Results reveal
that neuronal death did not increase over time, and similar results
were seen with satellite glia. No increase in cell death overtime of
PCI30 cells was seen, but instead a small but non-signiﬁcant
decrease was seen, presumably due to cell proliferation.
Interesting, mixed glial cell death appeared to increase over time
(Fig. 7–9).
3.9. Treatment of TPCS2a PDT and PCI combining Bleomycin reduced
neurite length
Neurite length was assessed following treatment with PDT and
PCI combining 0.07 IU/ml Bloemycin with 0.4 and 0.8 mg/ml
TPCS2a. And as before, light exposures of 5 mins were employed
and incubation with drugs for 18 hrs. Results reveal that both PDT
and PCI signiﬁcant reduced neurite length when compared to
Fig. 7. Sensitivity of cells to TPPS2a PCI of Bleomycin. PCI30, mixed glial cells neurons and satellite glia incubated with 0.2–0.8 mg/ml TPPS2a and 0.00175–0.07IU/ml of
Bleomycin for 18 hrs before irradiation using a LED light source. Two-way ANOVA revealed a main effect of cell type, as well as concentration of TPCS2a in increased cell death
and an interaction between cell type and TPCS2a concentration. Mean  SEM, n = 6.
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IU/ml Bleomycin alone however, did not affect neurite length.
4. Discussion
The overall aim of the project was to understand the effects of
PCI treatment on mammalian peripheral nerve cells in order to
minimise nerve toxicity in future clinical applications. This is the
ﬁrst study to investigate the effects of PCI upon nervous system
cells, which is an important consideration for developing PCI to
treat tumours adjacent to or within nervous system tissue. One of
the great therapeutic advantages that PDT has over surgery is
preservation of nerve function as the other main therapy for head
and neck cancer causes demyelination especially with irradiation.
We have shown in previous clinical studies that nerve function
remains intact after PDT treatment and this has been conﬁrmed
using in vitro models. Early indications are that nerve sparing is
also seen with PCI and this experimental study carried out under
controlled conditions indicates this is indeed the case.Using advanced cell culture models, the photosensitisers TPCS2a
and TPPS2a were investigated along with the chemotherapeutic
drug Bleomycin. Cells included neurons and glial cells from the
peripheral and central nervous system and controls used a relevant
head and neck cancer cell line, PCI30. These cell culture models
provide a powerful system in which to study neural cell responses
to PCI treatment as they can be tightly controlled and easily
monitored and are usually less expensive and less time consuming
than animal models (Grifﬁth and Swartz, 2006). The interactions
between neurons and glial cells are important in determining the
phenotype and survival of each and the 3D environment allows
neurons and glia to interact in a manner that mimics their
interdependence in neural tissue.
The key ﬁndings of this study is that DRG neurons are less
sensitive to TPCS2a and TPPS2a-mediated PCI than their associated
satellite glia and the tumour cell line PCI30, both of which
demonstrated a dose-dependent increase in cell death over a range
of photosensitiser and chemotherapeutic drug concentrations. CNS
glia (mixed glia) consisting of astrocyte, oligodendrocytes and
Fig. 8. Cell death 48 and 72 hours post PCI treatment with TPCS2a and Bleomycin.
PCI30, mixed glial cells, neurons and satellite glia incubated with 0.8 mg/ml TPCS2a
and 0.07IU/ml of Bleomycin for 18 hrs before irradiation using a LED light source.
Cell death was assessed after 24, 48 and 72 hours and one-way ANOVA revealed no
signiﬁcant increase in cell death over time. Mean  SEM, n = 6.
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death. These results suggest that DRG neurons are able to survive
PCI treatment with the chosen photosensitisers (TPCS2a and
TPPS2a) and Bleomycin treatments that kill tumour cells.
Firstly uptake of both TPCS2a and TPPS2a in neurons and satellite
glial, cancer cells and mixed glial cells was characterised revealing
that all cells were capable of taking up both photosensitisers and
that the cancer cell line exhibited greater uptake of TPCS2a when
compared with the primary cells. Comparing the photosensitiser
ﬂuorescence levels in each cell type, TPCS2a yielded higher
ﬂuorescence in all cell types compared to TPPS2a at the same
doses. This is in line with studies that have also examined uptake of
both photosensitisers (Martinez De Pinillos Bayona et al., 2017).
However since TPCS2a is a more efﬁcient ﬂuorophore than TPPS2a,
the higher intracellular ﬂuorescence does not imply that higher
concentrations of TPCS2a are taken up by cells (Lilletvedt et al.,
2010). Immunostaining conﬁrmed that the photosensitisers were
colocalised with Lysotracker Green, which is consistent with
endolysosomal localisation of the photosensitiser. Additionally it
was conﬁrmed that the presence of the photosensitisers in the
absence of light had no toxic effects upon cells. Phototoxicity of
TPCS2a and TPPS2a was assessed, which showed that the PCI30 cell
line was more susceptible to TPPS2a than primary neural cells,
whilst this pattern was not observed for TPCS2a.From these data,
the sub-lethal phototoxic threshold (PDT50 i.e. 50% cell death) of
light and photosensitiser (PDT) was established for subsequent
studies.
Bleomycin cytotoxicity is caused by single and double-stranded
DNA damage and at high doses can result in pneumonitis and
subsequent lung ﬁbrosis (Berg et al., 2005). PCI reduces the
Bleomycin dose required, and Berg et al., performed PCI using in
vitro and in vivo human sarcoma, human colorectal adenocarcino-
ma and murine colon carcinoma models using TPPS2a (0.7 mg
mL1) and Bleomycin (0.14 IU mL1). The study demonstrated that
use of Bleomycin in combination with PCI signiﬁcantly enhanced
cytotoxicity by a factor of three compared to Bleomycin alone in
vitro (Berg et al., 2005). The in vitro studies here demonstrated that
Bleomycin alone caused cell death of DRG and satellite glial cells,PCI30 cells and mixed glial cells and illumination of gels following
administration of Bleomycin did not increase death signiﬁcantly.
PCI studies combining Bleomycin with TPPS2a demonstrated a
dose dependent increase in cell death following 18 hours incuba-
tion with both photosensitiser and Bleomycin. Importantly the
cancer cell line was more susceptible to PCI than neurons, with
signiﬁcant differences observed between PCI30 and DRG neurons,
and at the highest concentrations of TPPS2a and Bleomycin used in
this study, twice the amount of PCI30 cells death than neurons.
These results suggest that PCI treatment combining TPPS2a and
Bleomycin has the potential to spare neurons whilst killing cancer
cells. Similarly, PCI studies combining Bleomycin with TPCS2a
demonstrated a dose dependent signiﬁcant increase in cell death
following 18 hours incubation with both photosensitiser and
Bleomycin. At higher concentrations of Bleomycin (0.07 IU/ml),
a signiﬁcant difference was observed between PCI30 cells and DRG
neurons, with reduced cell death observed in DRG neurons
suggesting TPCS2a and Bleomycin spare neurons whilst killing
cancer cells. However, it is important to note that as the
photosensitiser in PCI is located in close proximity to the molecule
to be internalised, photochemical treatment could potentially
damage not only the endosomal membrane, but also the molecule
to be internalised (Hogset et al., 2004). There have been several
studies that have indicated that endocytosed molecules may be
damaged by the PCI procedure (Berg et al.,1999, Prasmickaite et al.,
2000). This may explain why the highest concentrations of
photosensitiser do not results in increased cell death in PCI studies.
TPCS2a has been proposed as an optimal photosensitiser for
clinical PCI, owing to suitable photophysical and photobiological
properties (Wang et al., 2013, Berg et al., 2011) and more recently, a
phase 1 clinical trial has found that administration of TPCS2a is safe
and tolerable to human patients and identiﬁed 0.25 mg/kg as the
recommended treatment dose (Sultan et al., 2016). TPPS2a has been
investigated in vitro with promising results, however is less
suitable for clinical development since its red absorption is
comparatively weak (Martinez De Pinillos Bayona et al., 2016). As a
result, further studies were undertaken in which PCI using TPCS2a
and Bleomycin was investigated in more detail.
The potential nerve-sparing effects observed in vitro 24 h after
PCI treatment were investigated further by extending the time
between treatment and cell death analysis; as bleomycin induces
single and double-strand DNA damage cell death can occur at later
timepoints. There was no increase in neuron death detected at 48 h
and 72 h, conﬁrming that neurons survived PCI treatment over a
longer term. Importantly, despite the survival of DRG neurons, PCI
treatment caused as a substantial reduction in neurite length.
Wright et al. demonstrated a similar phenomenon; sparing of
neurons but a reduction in neurite length following mTHPC-
mediated PDT treatment (Wright et al., 2009). Since both that PDT
study and this PCI study used neurons in co-culture with glial cells,
which naturally provide trophic support to neurons, it is possible
that the reduction in neurite length was a consequence of glial cell
depletion rather than a direct effect of treatment on neurons. It will
be important to explore this further, since neurite damage without
neuronal death might provide an opportunity for any short-term
loss of function to be reversed.
PCI using Bleomycin has also been investigated for brain cancer.
In vivo studies showed improved survival of animals bearing the
F98 glioma model using a combination of Bleomycin PCI and an
epsilon prototoxin versus controls (Hirschberg et al., 2009).
However, whether there was an effects of PCI upon the
surrounding cellular environment, speciﬁc possible effects to
astrocytes, oligodendrocytes and microglia, was not described.
Here we report that mixed glial cells are similar to neurons; less
sensitive to PCI treatment than a cancer cell line, however, an
Fig. 9. Neurite length signiﬁcantly decreased following PDT and PCI treatment. (A) Neurite length of primary DRG neurons was signiﬁcantly reduced followed PDT treatment
using 0.4 and 0.8 mg/ml TPCS2a and PCI treatment in combination with 0.07IU/ml of Bleomycin (Bl) when compared to control. Mean  SEM, n = 6, One-way ANOVA with
Dunnett’s post hoc test, **p < 0.01, ***p < 0.001. (B) Fluorescence micrographs exhibit differences in neurons stained for b-III tubulin (green) post treatment.
142 C. O’Rourke et al. / International Journal of Pharmaceutics 528 (2017) 133–143
C. O’Rourke et al. / International Journal of Pharmaceutics 528 (2017) 133–143 143increase in cell death overtime i.e. 48 and 72 hours post PCI
treatment was noted.
This study indicates that PCI treatment combining Bleomycin in
combination with either TPCS2a or TPPS2a allows neurons to
survive but kills cancer cells and satellite glia. This offers the
potential for developing clinical PCI treatments for cancers within
or adjacent to sensitive nervous system tissue, e.g. cancers of the
head and neck, bladder, prostate and bone metastases in the spine.
The 3D co-culture models used here provided a useful insight into
the comparative sensitivity of different cell types to PCI. In an era of
organ preserving cancer therapy, PDT and PCI has shown in vitro
and in vivo to be function preserving therapies, especially in head
and neck cancer, where surgery has an adverse effect on functions
such as speech and swallowing.
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